The in-depth analysis of the CFTR gene, that consists in exploring all the coding exons their flanking regions and targeted intronic sequences, leads to the frequent identification of private point mutations in patients. It is difficult to establish a priori the effect of rare intronic, synonymous or missense variants on the function of the encoded protein and subsequently their involvement in the disease. Consequently, we previously designed a classification method for the evaluation of their impact on splicing which provides strong arguments to select variants that require further analysis of nasal epithelial cell transcripts in the patients. For this purpose, we have now developed a multiplex fluorescent PCR for the one-step analysis of alternative and/or aberrant splicing of CFTR mRNA. We designed four different mix, using FAM-labelled forward primers, that contain the whole CFTR transcript in 26 overlapping fragments. We also included an internal control amplifying a sequence of the ALAS1 transcript. PCR products were then analysed by relative quantification after capillary electrophoresis migration on the 3130XL Genetic Analyzer. In a first step we have set the optimal conditions for a balanced amplification of each amplicon using mRNA from T84 cells, known to express CFTR. The validation of this method is underway using mRNA from nasal epithelial cells of healthy individuals and patients carrying an identified splicing mutation. By quantifying aberrant splicing effect, this method should play its full role in the characterization and classification of rare genomic variants of unknown clinical significance.
12 Using a mRNA-based approach to detect rare CFTR mutations Due to the large extension of CFTR gene (~190kb) and the large number of gene variants reported (>1900) there's a need to establish quick methods for mutation analysis. Usually this is achieved by limiting analysis to the most common mutations. However, this often leads to difficulties in CF genotype identification, especially in populations with high prevalence on non-p.F508del mutations.
We have designed a mRNA-based protocol using just 9 RT-PCR reactions, hereby the complete CFTR coding region is analysed. Moreover, one of the reactions (exons 11−13) is based on ARMS for p.F508del mutation, which allows easy detection of this mutation. We have applied this protocol to genotype 12 CF patients with absence or just residual CFTR-mediated Cl − secretion in rectal biopsies and only 1 CFTR mutation identified by routine methods. Using this strategy we detected mRNA alterations in 75% of the patients and identified the 2 nd mutation, confirmed by genomic DNA sequencing. For 2 siblings we detected a cryptic exon between exons 10−11 resulting from a mutation far deep into IVS 10 (c.1584+18672A>G), unlikely to be detected by CFTR exon sequencing. The other mutations detected were: p.G576A, c.1717−1G>A, c.1812−1G>A, c.3272−26A>G, c.3120+1G>A (2P) (legacy nomenclature). We conclude that this is a rapid, robust and inexpensive method to detect rare mutations that can be easily used after a first screen. Furthermore it already demonstrates the functional consequences of mutations in case they occur at the RNA level. Supported by PEst-OE/BIA/UI4046/2011 BioFig centre grant and Ciência2008 fellowship to ASR (FCT, Portugal) and Gilead MED-2012-131 grant.
